A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells
- 61 Downloads
The effects of a vasoactive intestinal peptide (VIP) receptor antagonist (VIPhyb) on human glioblastoma cells were characterized. Pituitary adenylate cyclase activating polypeptide (125I-PACAP-27) bound with high affinity to U87, U118, and U373 cells. Specific 125I-PACAP-27 binding to U87 cells was inhibited, with high affinity, by PACAP but not VIP or VIPhyb (IC50=10, 1500, and 500 nM, respectively). By reverse transcriptasepolymerase chain reaction (RT-PCR), a major 305bp band was observed indicative of PAC1 receptors. PACAP-27 caused cAMP elevation and the increase in cAMP caused by PACAP-27, was inhibited by the VIPhyb. Also, PACAP-27 caused cytosolic Ca2+ elevation in Fura-2AM loaded U87 cells and the VIPhyb inhibited this increase. Using the MTT growth assay, the VIPhyb was shown to inhibit glioblastoma growth in a concentration-dependent manner. Using a clonogenic assay in vitro, 10 µM VIPhyb significantly inhibited proliferation of U87, U118, and U373 cells. In vivo, 0.4 µg/kg VIPhyb inhibited U87 xenograft proliferation in nude mice. These results suggest that the VIPhyb antagonizes PAC1 receptors on glioblastoma cells and inhibits their proliferation.
Index EntriesPACAP receptors glioblastoma VIP antagonist proliferation
Unable to display preview. Download preview PDF.
- Arimura A. (1992) Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. Reg. Peptides 37, 287–303.Google Scholar
- Gozes I., McCune S. K., Jacobson L., Warren D., Moody T. W., Fridkin M., and Brenneman D. E. (1991) An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J. Pharm. Exp. Ther. 257, 959–966.Google Scholar
- Levin V. A., Leibel S. A., and Gutin P. H. (1997) Neoplasms of the central nervous system, in Cancer Principles and Practice of Oncology (DeVita V. T. Jr., Hellman S., and Rosenberg S. A., eds.), Lippincott-Raven Publishers, Philadelphia New York, pp. 2022–2082.Google Scholar
- Lilling G., Wollman Y., Goldstein M. N., Rubinraut S., Fridkin M., Brenneman D. E., and Gozes I. (1995) Inhibition of human neuroblastoma growth by a specific VIP antagonist. J. Mol. Neurosci. 5, 231–239.Google Scholar
- Magistretti P. J., Morrison J. H., Shoemaker W. J., Sapin V., and Bloom F. E. (1981) Vasoactive intestinal polypeptide induces glycogenolysis in mouse cortical slices: a possible regulatory mechanism for the local control of energy metabolism. Proc. Natl. Acad. Sci. USA 78, 6535–6539.PubMedCrossRefGoogle Scholar
- Mantey S. A., Weber H. C., Sainz E., Akeson M., Ryan R. R., Pradhan T. K., et al. (1997) Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors. J. Biol. Chem. 272, 26,062–26,071.CrossRefGoogle Scholar
- Maruno K. and Said S. I. (1993) Human small cell lung carcinoma inhibition by vasoactive intestinal peptide (VIP) and helodermin (Hd). Biomed. Res. 13, 373–375.Google Scholar
- Moody T. W., Staley J., Zia F., Coy D. J., and Jensen R. T. (1992) Neuromedin B receptors are present on small cell lung cancer cells. J. Pharmacol. Exp. Therap. 263, 311–317.Google Scholar
- Moody T. W., Zia F., Goldstein A., Naylor P., Sarin E., Brenneman D., et al. (1993a) VIP analogues inhibit small cell lung cancer growth. Biomed. Res. 13, 131–136.Google Scholar
- Spengler D., Waeber C., Pantaloni C., Holsboer F., Bockaert J., Seeburg P. H., and Journot L. (1993) Differential signal transduction by five splice variants of the PACAP receptor.Google Scholar
- Waelbroeck M., Robberecht P., Coy D. H., Camus J. C., De Neef P., and Christophe J. (1985) Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1, D-Phe2)-GRF (1-29)-NH2 as a VIP antagonist. Endocrinology 116, 2643–2649.PubMedCrossRefGoogle Scholar